NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer

Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thus their potential for NIR-II FGS in the cancer setting.

Automated summary

Using fluorescence-guided surgery (FGS) with NIR-II dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors showed favorable tumor accumulation and selective targeting of HER2 positive tumors. These bioconjugated NIR-II-emitting dyes displayed prolonged stability in serum and maintained affinity toward HER2 in vitro, indicating their potential for NIR-II FGS in the cancer setting. This study suggests that the use of NIR-II dyes in FGS can improve the complete resection of microscopic ovarian tumors.